Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VELCADE · 2 trials · 2 indications
Maximum Tolerated Dose (MTD) was defined as the highest dose level that has 0/1 out of 6 patients experiences Dose Limited Toxicity (DLT). MTD is defined separately for QW and BIQ dose cohorts. DLT was defined as adverse events occurring during Cycle 1 and: (1) related to VELCADE, (2) Grade 4 thrombocytopenia or neutropenia, (3) Grade 3 or higher nonhematologic toxicity.
Treatment emergent adverse events observed during outcome measure time frame
Serious treatment emergent adverse events observed during outcome measure time frame
Grade 3/4/5 treatment emergent adverse events observed during outcome measure time frame. Grade is determined according to Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0.
Treatment emergent adverse events observed during outcome measure time frame leading to treatment termination
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | VELCADE |
| Name | Type | Description |
|---|---|---|
| VELCADE | DRUG | - |
| Alimta | DRUG | - |
Inclusion Criteria: * Men or women, 18 years of age or older * Non-small cell lung cancer (NSCLC) has been histologically or cytologically confirmed * Has relapsed or refractory locally advanced (Stage IIIb) or metastatic (Stage IV) NSCLC * Failed one prior line of systemic antineoplastic therapy f...
Top 20 of 84 competitors
VELCADE is a small molecule being studied for use in Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, and Amyloidosis. It is an investigational drug in clinical development for these conditions. VELCADE is developed by Takeda Pharmaceutical Company Limited.
VELCADE is a small molecule therapeutic. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being evaluated in clinical studies for Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, and Amyloidosis.
VELCADE is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical trials of VELCADE for Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, and Amyloidosis.
VELCADE is in Phase 1 clinical development. It has completed one Phase 1 trial, one Phase 2 trial, and one Phase 3 trial. VELCADE is not approved and remains investigational for the studied indications.
VELCADE has been studied in clinical trials including NCT00298766, an open-label Phase 1/2 study in patients with light-chain (AL)-amyloidosis, and NCT00722137, a Phase 3 study in patients with newly diagnosed Mantle Cell Lymphoma. These trials are completed.
VELCADE is also known as bortezomib. Clinical trials refer to the drug as VELCADE for injection and VELCADE (bortezomib). It is being studied for Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, and Amyloidosis.